Mark D. Perrin

CEO/Chairman of the Board

Mr. Perrin is an experienced senior executive and leader with demonstrated success in building businesses, commercializing products, business development, and raising capital. Before joining InVivo Therapeutics in January 2014, he served as President of Dennan Consulting, a biotech consulting firm. From 2005 to 2010, he served as President and Chief Executive Officer of ConjuChem Biotechnologies, a company developing long-acting conjucated pepitide therapeutics. While at Conjuchem, Mr. Perrin significantly advanced the company’s product portfolio while raising over $150 million in new equity financing. From 2002 to 2005, he was Executive Vice President and Chief Commercial Officer for Orphan Medical, a company focused on drug development for orphan diseases, principally in the central nervous system therapeutic areas. While at Orphan Medical, he built the central nervous system specialty sales force and directed all commercial activities for the successful launch of the company’s first major commercial product. Mr. Perrin spearheaded the effort, which led to Orphan Medical’s acquisition by Jazz Pharmaceuticals for over $120 million. Prior to that, he was the Executive Vice President, Commercial Operations for COR Therapeutics from 1995 to 2001. He managed all aspects of prelaunch and launch activities and, as a result, the company captured number one market share within two years over competitive Eli Lilly and Merck. Earlier in his career he was Vice President for Burroughs Wellcome and for Lederle Laboratories, with responsibility for U.S. commercial operations at each company.

Mr. Perrin earned his Bachelor of Science degree in economics from Fordham University and Master of Business Administration degree in marketing and international business from the Kellogg Graduate School of Management at Northwestern University.